Italia markets closed

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
38,14+0,49 (+1,30%)
Al 12:00PM EST. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente37,65
Aperto37,52
Denaro38,23 x 1100
Lettera38,28 x 800
Min-Max giorno37,34 - 38,36
Intervallo di 52 settimane34,86 - 53,23
Volume752.037
Media Volume2.559.439
Capitalizzazione16,382B
Beta (5 anni mensile)N/D
Rapporto PE (ttm)19,80
EPS (ttm)1,93
Prossima data utili15 feb 2022 - 21 feb 2022
Rendimento e dividendo (forward)0,68 (1,75%)
Data ex dividendo18 nov 2021
Stima target 1A51,43
  • GlobeNewswire

    Royalty Pharma to Present at Evercore ISI 4th Annual HealthCONx Virtual Conference

    NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021 at 9:40 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is

  • GlobeNewswire

    Royalty Pharma Acquires Additional Royalty Interests in BCX9930 and ORLADEYO from BioCryst Pharmaceuticals

    Provides funding for BCX9930/oral Factor D program across multiple indicationsAgreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closi

  • GlobeNewswire

    Royalty Pharma Reports Third Quarter 2021 Results

    Net cash provided from operating activities (GAAP) of $470 million; Adjusted Cash Receipts(1) (non-GAAP) of $587 million and Adjusted Cash Flow(2) (non-GAAP) of $441 millionAnnounced transactions of up to $2.8 billion in 2021, including $2.1 billion in upfront paymentsRaises 2021 guidance: Adjusted Cash Receipts(1) expected to be $2,110 to $2,130 million NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2021 an